美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

ARIA Opportunities ETF

25.99

-0.3848-1.46%

成交量：11

成交额：287

市值：1,255.68万

市盈率：- -

高：25.99

开：26.37

低：25.99

收：26.37

52周最高：26.76

52周最低：24.54

股本：48.32万

流通股本：48.32万

量比：0.08

换手率：0.00%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

ARIA Opportunities ETF

交易所：

ARCA

成立时间：

2026

员工人数：

- -

公司地址：

10900 Hefner Pointe Drive,Suite 400,Oklahoma City,Oklahoma,United States

官网：

http://www.ariad.com

邮编：

73120

电话：

传真：

405-896-5825

简介：

ARIAD Pharmaceuticals, Inc.的前景是通过具有突破性的药物治疗癌症患者。该公司致力于发现、开发和推广小分子药物来治疗癌症患者，满足患者最迫切的医疗需求——目前无法治疗的侵略性癌症。该公司的目标是建立一个完全集成的肿瘤学公司。该公司目前有三个正在开发中的候选产品。白血病药物Ponatinib正处于血液肿瘤患者临床试验的第一阶段和第二阶段，包括慢性髓性白血病和费城阳性急性淋巴细胞白血病的临床试验。药物AP26113正处于治疗晚期实体肿瘤的临床试验的第一阶段和第二阶段。药物Ridaforolimus正处于研究不同类型癌症患者的多个临床试验中。根据附注2所述的许可协议的条款，默克股份有限公司（ Merck, Sharpe & Dohme Corp. ）负责药物Ridaforolimus相关的开发、制造和推广活动。除了公司的主导发展计划，该公司重点放在分子靶向癌症细胞信号通路的小分子疗法的针对性药物研发项目。该公司于1991年4月在特拉华州注册成立。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/ARIA/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARIA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARIA\",,,,,undefined,":{"symbol":"ARIA","market":"US","secType":"STK","nameCN":"ARIA Opportunities ETF","latestPrice":25.9868,"timestamp":1791835200000,"preClose":26.3716,"halted":0,"volume":11,"delay":0,"changeRate":-0.014591454443416479,"floatShares":483200,"shares":483200,"eps":0,"marketStatus":"盘前交易","change":-0.3848,"latestTime":"10-13 04:06:22 EDT","open":26.3716,"high":25.9868,"low":25.9868,"amount":287,"amplitude":0,"askPrice":41.31,"askSize":100,"bidPrice":10.66,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791898200000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":25.9868,"nav":26.33,"aum":12722720.39,"bidAskSpread":0,"volumeRatio":0.07812492231896928},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARIA\",,,,,undefined,":{"symbol":"ARIA","floatShares":483200,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.07812492231896928,"shares":483200,"dividePrice":0,"high":25.9868,"amplitude":0,"preClose":26.3716,"low":25.9868,"week52Low":24.5362,"pbRate":"--","week52High":26.7557,"institutionHeld":0.5771,"latestPrice":25.9868,"eps":0,"divideRate":0,"volume":11,"delay":0,"ttmEps":0,"open":26.3716,"prevYearClose":24.76,"prevWeekClose":26.3716,"prevMonthClose":25.5521,"prevQuarterClose":25.5521,"fiveDayClose":25.9041,"twentyDayClose":25.8299},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARIA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARIA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARIA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1992791129,"yearFounded":2026,"address":"10900 Hefner Pointe Drive,Suite 400,Oklahoma City,Oklahoma,United States","zipCode":"73120","officePhone":"405-778-8377","officeFax":"405-896-5825"},"stockCompanyDetail":{"websiteUrl":"http://www.ariad.com","stockEarnings":[{"period":"1week","weight":0.0032},{"period":"1month","weight":-0.0042},{"period":"3month","weight":0.0495},{"period":"ytd","weight":0.0495}],"compareEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":0.0181},{"period":"3month","weight":0.0349},{"period":"6month","weight":0.1117},{"period":"1year","weight":0.1915},{"period":"ytd","weight":0.141}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ARIAD Pharmaceuticals, Inc.的前景是通过具有突破性的药物治疗癌症患者。该公司致力于发现、开发和推广小分子药物来治疗癌症患者，满足患者最迫切的医疗需求——目前无法治疗的侵略性癌症。该公司的目标是建立一个完全集成的肿瘤学公司。该公司目前有三个正在开发中的候选产品。白血病药物Ponatinib正处于血液肿瘤患者临床试验的第一阶段和第二阶段，包括慢性髓性白血病和费城阳性急性淋巴细胞白血病的临床试验。药物AP26113正处于治疗晚期实体肿瘤的临床试验的第一阶段和第二阶段。药物Ridaforolimus正处于研究不同类型癌症患者的多个临床试验中。根据附注2所述的许可协议的条款，默克股份有限公司（ Merck, Sharpe & Dohme Corp. ）负责药物Ridaforolimus相关的开发、制造和推广活动。除了公司的主导发展计划，该公司重点放在分子靶向癌症细胞信号通路的小分子疗法的针对性药物研发项目。该公司于1991年4月在特拉华州注册成立。","exchange":"ARCA","name":"ARIA Opportunities ETF","nameEN":"ARIA Opportunities ETF"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ARIA\",market:\"US\",,,undefined,":null}}